EXPLAINER: 3 Blood Tests Your Doctor Skips (That Predict Heart Attacks & Alzheimer's)

Your doctor orders a lipid panel every year — but 3 cheap blood tests predict heart disease, diabetes, and even dementia far better than cholesterol, and most doctors never order them.

In this episode, Robert Lufkin MD walks through fasting insulin + HOMA-IR, homocysteine, and high-sensitivity CRP — three tests that together cost about $60, take one blood draw, and catch the metabolic dysfunction a standard lipid panel systematically misses.

CHAPTERS:

• 00:00 — The 3 Blood Tests Your Doctor Isn't Ordering
• 00:40 — Part 1: Fasting Insulin and HOMA-IR
• 01:15 — How Insulin Resistance Hides for 10–15 Years
• 01:45 — HOMA-IR vs Glucose: What 516,000 People Revealed
• 02:05 — 59% Higher Cardiovascular Risk in the 2023 ATVB Study
• 02:45 — Optimal Fasting Insulin: Why 5–8 Beats the Lab's "25"
• 03:05 — Part 2: Homocysteine and the MTHFR Connection
• 03:35 — How Homocysteine Damages Your Arteries (6 Mechanisms)
• 03:50 — 60% Higher Stroke Risk and 48% Alzheimer's Risk
• 04:35 — The Oxford VITACOG Trial: 53% Less Brain Atrophy
• 05:05 — Part 3: High-Sensitivity CRP and Inflammatory Plaque
• 05:40 — The JUPITER Trial: 44% Drop in Cardiac Events
• 06:15 — UK Biobank: Why hs-CRP Beats LDL Cholesterol
• 06:50 — AHA Risk Categories for hs-CRP Since 2003
• 07:15 — Part 4: The Metabolic Picture (Why Cholesterol Is the Wrong Target)
• 07:50 — 3 Tests, $60, One Blood Draw — The Full Framework

KEY TAKEAWAYS:

• Fasting insulin + HOMA-IR catches insulin resistance a decade before glucose goes abnormal — optimal is below 5–8, not the lab's reference range of 25
• Every 5 µmol/L rise in homocysteine raises coronary artery disease risk 20–30% and stroke risk 60%, independent of cholesterol
• hs-CRP predicted cardiovascular events better than LDL in a 322,000-person UK Biobank analysis — yet fewer than 10% of cardiac panels order it
• Cardiovascular disease, type 2 diabetes, and dementia share the same upstream driver: metabolic dysfunction, not cholesterol
• All three tests together cost roughly $60 and come from a single blood draw

LINKS:
📖 Dr. Lufkin's book "Lies I Taught in Medical School": robertlufkinmd.com/lies
📰 Substack: robertlufkinmd.substack.com
🌐 Website: robertlufkinmd.com
▶️ Watch on YouTube: youtu.be/FBLB1CQGBPM

⭐ Enjoying the show? Please leave a 5-star review on Apple Podcasts — it takes 30 seconds and helps more people discover the science of health and longevity. Thank you!

New episodes every Tuesday & Thursday. Subscribe so you don't miss one.

Continue this conversation on Substack: https://robertlufkinmd.substack.com
Lies I Taught In Medical School — Free sample chapter: https://www.robertlufkinmd.com/lies/

Web: https://www.robertlufkinmd.com
YouTube: https://www.youtube.com/robertlufkinmd
X: https://x.com/robertlufkinmd
Instagram: https://www.instagram.com/robertlufkinmd/
TikTok: https://www.tiktok.com/@robertlufkin
LinkedIn: https://www.linkedin.com/in/robertlufkinmd/

Transcript

Why Cholesterol Misses The Risk

SPEAKER_00 0:00

Your doctor orders a lipid panel every year. You know, total cholesterol, LDL, HDL, and triglycerides. If the numbers look fine, you're told you're healthy. But there are three blood tests that predict heart disease, diabetes, and even dementia more accurately than cholesterol. And most doctors never even order them. They're inexpensive, they're available at any lab, and they catch the metabolic dysfunction that cholesterol testing systematically misses. I'm Dr. Robert Lufkin, physician, medical school professor, and here are the three tests you should be asking for. Part one, fasting insulin and HOMA-IR. The first test is fasting insulin and its calculated companion, HOMA IR. Here's the problem. You have completely normal blood sugar and completely normal cholesterol while being deeply insulin resistant. Your pancreas is simply working harder to compensate, pumping out more and more insulin to keep the glucose in range. This state can persist for 10 to 15 years before your glucose ever goes abnormal. By the time a standard glucose test catches it, you've lost a decade of intervention time. According to the CDC, 115 million American adults have prediabetes. Eight in 10 of them don't even know it. Standard testing misses them. A meta-analysis of 65 studies involving over 516,000 people published in POS 1 found that HOMA IR, a simple calculation using fasting insulin and glucose, predicted coronary heart disease better than either glucose or insulin alone. The risk increase was 46% standard deviation increase in HOMA IR compared to just 21% for glucose. And a 2023 study in atherosclerosis, thrombosis, and vascular biology tracked over 6,700 adults for nearly a decade and found that people using HOMA IR trajectory had 59% higher cardiovascular disease incidence and 367% higher risk of dying from a major cardiac event even after adjusting for obesity. In non-obese individuals with low baseline risk, rising HOMA IR predicted nearly six times the cardiac mortality. The conventional lab reference range for fasting insulin goes up to 25, but that reflects a metabolically sick population already. Optimal is below 5 to 8. Ask for it, and it costs less than$30. Part two, homocysteine. The second test is homocysteine. Homocysteine is an amino acid your body produces when it metabolizes protein. Normally it's recycled using B vitamins, you know, folate, B12, and B6. When those are insufficient or when you carry genetic variants like the MTHFR that slow the recycling, homocysteine builds up. And elevated homocysteine directly damages the lining of your arteries through at least six distinct mechanisms. And this is independent of your cholesterol level. The epidemiological data is massive. Every 5 micromole per liter increase in homocysteine is associated with a 20 to 30% higher risk of coronary artery disease and a 60% higher risk of stroke. A separate meta-analysis of over 7,400 people found that elevated homocysteine increased Alzheimer's disease risk by 48%. Most doctors stopped ordering this test after several B vitamin trials in the early 2000s appeared negative, but those trials enrolled patients who already had advanced cardiovascular disease or they used the wrong form of B12 and were conducted in countries which already had folic acid food fortification, which had already partially lowered the baseline levels. When the Oxford Vitacog trial tested B vitamins in people with mild cognitive impairment and elevated homocysteine, brain atrophy slowed by 30% overall and by 53% in those with the highest levels. Standard labs don't flag homocysteine until it's above 15, but the risk gradient starts rising above 10. And optimal is really below 8. It's a$15 test, and if it's elevated, the solution is straightforward: methylfolate, methylcobalamin, and B6. Part three. High sensitivity CRP. The third test is high sensitivity C reactive protein, HSCRP. Atherosclerosis is an inflammatory disease. Cholesterol is part of the story, but plaque formation, progression, and rupture are all driven by inflammation. And a person with an LDL of 60 and an HSCRP of 5 is at far greater risk than someone with an LDL of 130 and an HSCRP of 0.3. The lipid panel alone would flag the wrong patient. The landmark Jupiter trial, published in the New England Journal of Medicine, enrolled nearly 18,000 apparently healthy people with normal LDL, think you know, below 130, but elevated HSCRP above 2. These people were invisible to standard cholesterol screening. When treated with a statin, their cardiovascular events dropped by 44%, heart attacks dropped 54%, strokes dropped 48%, and a 2020 UK Biobank analysis of over 322,000 people, followed for nearly 14 years, found that HSCRP ranked above LDL cholesterol in predicting major cardiovascular events, cardiovascular death, and all-cause death. By adding HSCRP to standard risk models, this improved accuracy by over 14%. The American Heart Association has endorsed HSCRP risk categories since 2003. Below one is low risk, one to three is moderate, above three is high. So optimal is really below one. It costs about$15 to$25, and yet surveys suggest it's ordered in fewer than 10% of routine cardiovascular panels. Part 4. The metabolic picture. Okay, here's the bottom line. Cholesterol testing was designed for a model of heart disease that treats it as a plumbing problem. You know, too much fat clogging your pipes. But the science now shows that cardiovascular disease, type 2 diabetes, and even dementia share a common upstream driver, metabolic dysfunction, insulin resistance, chronic inflammation, impaired methylation. Fasting insulin catches insulin resistance a decade before glucose does. Homocysteine catches methylation failure and endothelial damage that cholesterol doesn't even touch. And HSCRP catches the inflammatory fire that actually ruptures plaques, regardless of how much cholesterol is in them. Together, these three tests cost about$60. They take one blood draw and they tell you more about your actual metabolic health than a lipid panel ever will. This is the framework I lay out in my book, Lies I Taught in Medical School. We've been measuring the wrong things and treating the wrong targets. It's time to look upstream. I'm Dr. Robert Lufkin. If this changed what you'll ask your doctor for, subscribe and share this with someone who needs to hear it.